Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADAM12
REST API REST API
Homo sapiens
ADAM12 is differentially expressed in 307 experiments: 161 organism parts: prostate, placenta, ... (159 more);, 206 disease states: normal, glioblastoma, ... (204 more);, 106 cell types 392 cell lines 34 compound treatments and 79 other conditions.
Synonyms MLTN, MCMPMltna
Orthologs Adam12 (Mus musculus)   ADAM12 (Gallus gallus)   ADAM12 (Bos taurus)   ADAM12 (Danio rerio)   Adam12 (Rattus norvegicus)   adam12 (Xenopus laevis)   ADAM12 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, metalloendopeptidase activity, epidermal growth factor receptor signaling pathway, metallopeptidase activity, myoblast fusion, peptidase activity, SH3 domain binding, metal ion binding, extracellular region, cell adhesion, proteolysis, integral to membrane, zinc ion binding
InterPro Term Peptidase_M12B_N, Blood-coag_inhib_Disintegrin, ADAM_Cys-rich, EGF_3, Peptidase_M12B
UniProt Accession O43184, Q5JRP2, E9PBV4
Search EB-eye ENSG00000148848
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-4717, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
A549
2
E-GEOD-6013, E-GEOD-3202
HCC1143
2
E-MTAB-37, E-MTAB-62
PC3
2
E-GEOD-5258, E-GEOD-14464
BT474
1
2
E-MTAB-37, E-MEXP-440, E-MTAB-62
HuT78
1
E-MTAB-37
386 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (51 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-3982, E-GEOD-360
monocyte
1
2
E-MEXP-2019, E-GEOD-5099, E-GEOD-11755
plasmablast
1
E-MEXP-2360
nTreg
1
E-GEOD-22045
ovarian cancer
1
E-GEOD-21154
erythropoietic
1
E-GEOD-9894
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (65 experiments)

Factor Value U/D Experiments
glioblastoma
5
E-GEOD-4290, E-GEOD-6014, E-MTAB-37, E-MTAB-62, E-GEOD-4412 ... (5 experiments)
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
1
3
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
prostate carcinoma
1
3
E-GEOD-7307, E-MTAB-62, E-MTAB-37, E-GEOD-3868
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
200 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-5741, E-GEOD-5824, E-GEOD-5099, ... (22 experiments)

Factor Value U/D Experiments
none
3
6
E-GEOD-5741, E-GEOD-412, E-MEXP-1958, E-GEOD-4600, E-GEOD-5824, ... (9 experiments)
estradiol
1
E-GEOD-20081
valproic acid
1
E-GEOD-1615
rapamycin
1
E-GEOD-5824
TGF-Beta1
1
E-MEXP-2645
Cxcl12
1
1
E-GEOD-7307
28 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
127.57
1
1
E-TABM-325


Age at diagnosis
studied in E-GEOD-4922

Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-5372, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MEXP-2283, ... (7 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-19665

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1045, E-GEOD-3494, E-GEOD-2466, E-GEOD-22593, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-118, ... (32 experiments)

Infection
studied in E-GEOD-697, E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, ... (8 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-22229, E-GEOD-21750, E-GEOD-17636, E-GEOD-2487, ... (7 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-22541, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Processing time: 0.351 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM